Ocular Therapeutix (NASDAQ:OCUL) jumps 10% in after-hours trading after getting a permanent J-code for Dextenza 0.4 mg for intracanalicular use from the Centers for Medicare and Medicaid Services.
The J-code becomes effective today and will
replace the previously issued C-code, which became effective July 1,
2019. The company will retain transitional pass-through status granted
for Dextenza from CMS.
“J-codes are more widely recognized by commercial
insurance and Medicare Advantage and Part B plans, and physician
familiarity with J-codes should allow for a simpler and more convenient
reimbursement process that we believe will further contribute to
DEXTENZA’s commercial potential,” said Ocular President and CEO Anthony
Mattessich.
https://seekingalpha.com/news/3503121-ocular-therapeutixs-dextenza-gets-permanent-j-code-cms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.